Cargando…

How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer

The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this therapy in patients with mediastinal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kunitoh, H, Suzuki, K
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359947/ https://www.ncbi.nlm.nih.gov/pubmed/17473830 http://dx.doi.org/10.1038/sj.bjc.6603751

Ejemplares similares

Optimal surgical timing and radiotherapy dose for trimodality therapy in locally advanced non‐small cell lung cancer
por: Han, James E., et al.
Publicado: (2021)

Select octogenarians with stage IIIa non–small cell lung cancer can benefit from trimodality therapy
por: Tang, Andrew, et al.
Publicado: (2022)

Evaluation of Failure Patterns Using Trimodality in Non-Small Cell Lung Cancer
por: Patel, Shilpen, et al.
Publicado: (2011)

Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma
por: Goense, Lucas, et al.
Publicado: (2018)

Trimodality Therapy vs Definitive Chemoradiation in Older Adults With Locally Advanced Esophageal Cancer
por: Gaber, Charles E, et al.
Publicado: (2022)

Skeletal muscle area predicts the outcomes of non-small-cell lung cancer after trimodality therapy
por: Watanabe, Kenji, et al.
Publicado: (2023)

Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer
por: Guo, Yadong, et al.
Publicado: (2019)

Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis
por: Askoxylakis, Vasileios, et al.
Publicado: (2014)

Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy
por: Nevala-Plagemann, Christopher, et al.
Publicado: (2018)

Trimodality Treatment of Superior Sulcus Non-Small Cell Lung Cancer: An Institutional Series of 47 Consecutive Patients
por: Rzyman, Witold, et al.
Publicado: (2023)

Trimodal therapy in squamous cell carcinoma of the esophagus
por: Matuschek, C, et al.
Publicado: (2011)

Anaplastic thyroid cancer: outcomes of trimodal therapy
por: Houlihan, Orla A., et al.
Publicado: (2021)

Trimodality therapy in variant urothelial carcinoma: choose wisely
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2017)

Clinical outcomes of pancoast tumors treated with trimodality therapy
por: Lin, Tami Yu-Yu, et al.
Publicado: (2021)

Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy
por: Ozyurt, Hazan, et al.
Publicado: (2023)

Risk stratification of postoperative cardiopulmonary toxicity after trimodality therapy for esophageal cancer
por: Kowalchuk, Roman O., et al.
Publicado: (2023)

Trimodal Therapy: A Tumor Vascular‐Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia (Adv. Sci. 8/2018)
por: Luan, Xin, et al.
Publicado: (2018)

Personalized trimodal prehabilitation for gastrectomy
por: Bausys, Augustinas, et al.
Publicado: (2020)

Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer
por: Jeremić, Branislav, et al.
Publicado: (2018)

Feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer
por: Tanahashi, Masayuki, et al.
Publicado: (2020)

Application of contrast-enhanced CT radiomics in prediction of early recurrence of locally advanced oesophageal squamous cell carcinoma after trimodal therapy
por: Tang, Sun, et al.
Publicado: (2021)

The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy
por: Yang, Hui, et al.
Publicado: (2021)

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer
por: Turgeon, Guy-Anne, et al.
Publicado: (2014)

Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face
por: Block, Alec M., et al.
Publicado: (2015)

The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer
por: Russell, Christopher M., et al.
Publicado: (2016)

Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials
por: Tanai, C, et al.
Publicado: (2009)

Local ablative therapy of brain metastasis from non-small cell lung cancer: benefits and limitations
por: de Azevedo Rosas, Felipe, et al.
Publicado: (2021)

Trimodal therapy in T2‐4aN0M0 bladder cancer––How to select the best candidate?
por: Gofrit, Ofer N., et al.
Publicado: (2020)

Definitive re-irradiation of locally recurrent esophageal cancer after trimodality therapy in patients with a poor performance status
por: W. Kim, Daniel, et al.
Publicado: (2020)

Bipolar disorder: Trimodal age‐at‐onset distribution
por: Bolton, Sorcha, et al.
Publicado: (2020)

Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer—results from a retrospective analysis
por: Joosten, Pieter J M, et al.
Publicado: (2021)

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
por: Reynolds, John V, et al.
Publicado: (2023)

Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2021)

Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer
por: Vyfhuis, Melissa A.L., et al.
Publicado: (2017)

Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer
por: Kim, D. Nathan, et al.
Publicado: (2012)

Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?
por: Zhang, Zhenyang, et al.
Publicado: (2020)

Ion therapy within the trimodal management of superior sulcus tumors: the INKA trial
por: Hauswald, Henrik, et al.
Publicado: (2015)

Radiation dose mapping and anastomotic complications after trimodality therapy for esophageal cancers
por: Bang, Andrew, et al.
Publicado: (2019)

pH-responsive perylenediimide nanoparticles for cancer trimodality imaging and photothermal therapy
por: Li, Jianhao, et al.
Publicado: (2020)

The Use of Trimodality Treatment in Patients With Locally Advanced Oesophageal Squamous Cell Carcinoma: An Experience From a Large Cancer Centre in Pakistan
por: Qamar, Muhammad Fawad Ul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ghkmdjgcv2g0lvlo9ar5p43vmk